MARKET

ABOS

ABOS

Acumen Pharmaceuticals, Inc.
NASDAQ
3.795
-0.095
-2.44%
Opening 13:11 04/12 EDT
OPEN
3.850
PREV CLOSE
3.890
HIGH
3.930
LOW
3.760
VOLUME
102.69K
TURNOVER
0
52 WEEK HIGH
11.31
52 WEEK LOW
1.810
MARKET CAP
228.00M
P/E (TTM)
-3.5224
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ABOS last week (0401-0405)?
Weekly Report · 4d ago
Acumen Pharmaceuticals partners with Lonza to advance sabirnetug for the treatment of Alzheimer’s
Healthcare Acumen Pharmaceuticals partners with Lonza to advance sabirnetug for the treatment of Alzheimer’s. Acumen will manufacture an antibody targeting toxic soluble AβOs to treat the disease. Lonza will manufacture the drug substance in Portsmouth, New Hampshire.
Seeking Alpha · 04/04 13:01
ACUMEN PHARMACEUTICALS INC: ON TRACK TO INITIATE A PHASE 2 CLINICAL TRIAL EVALUATING SABIRNETUG IN FIRST HALF OF 2024
Reuters · 04/04 12:01
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
Acumen Pharmaceuticals is developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease. The company has signed a collaboration agreement with Lonza. The agreement covers the manufacture of an antibody targeting toxic soluble AβOs for treatment of AD.
Barchart · 04/04 07:00
Analysts Offer Insights on Healthcare Companies: LAVA Therapeutics (LVTX), Acumen Pharmaceuticals (ABOS) and Advanced Medical Solutions (GB:AMS)
TipRanks · 04/03 09:10
Weekly Report: what happened at ABOS last week (0325-0329)?
Weekly Report · 04/01 09:08
Acumen Pharmaceuticals (ABOS) Upgraded to Buy: What Does It Mean for the Stock?
NASDAQ · 03/28 16:00
Acumen Pharmaceuticals files for $200M mixed shelf offering
Acumen Pharmaceuticals files for $200M mixed shelf offering. The company filed a prospectus related to a proposed mixed shelf offer of up to $200 million. The stock is down 2.7% in the last week. Acumen Pharmaceutical, Inc. (ABOS) is a biotechnology company.
Seeking Alpha · 03/27 20:58
More
About ABOS
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on advancing a targeted immunotherapy drug candidate, ACU193, and establishing proof of mechanism in early AD patients. The Company's ACU193 is a humanized monoclonal antibody that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The Company's therapeutic approach focuses on targeting AbOs, which is a toxic and pathogenic form of Ab relative to Ab monomers and amyloid plaques. The Company is developing ACU193 for intravenous (IV), administration every four weeks for the treatment of early AD, which is in Phase I clinical trial.

Webull offers Acumen Pharmaceuticals Inc stock information, including NASDAQ: ABOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABOS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABOS stock methods without spending real money on the virtual paper trading platform.